Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Sotelo-Alva MI, Beyar-Katz O, Yan J, Escribano-Serrat S, Boardman A, Geva M, Gomez-Llobell M, Halloun J, Khatib H, Hultcrantz M, Lue J, Mailankody S, Papanicolaou G, Palomba L, Park JH, Rejeski K, Sanz J, Scordo M, Seo SK, Shah G, Shi K, Shibli N, Usmani S, Nishimura N, Shahid Z, Perales MA, Shouval R, Kamboj M, Einarsdottir S. Respiratory Syncytial Virus After Chimeric Antigen Receptor T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort. Clin Infect Dis. 2026 Apr 30; 82(4):618-621.
-
Hansen DK, Dima D, Mian H, Devos J, Brazauskas R, Oloyede T, Afrough A, Ahmed N, Anderson L, Banerjee R, Berdeja JG, Bidikian A, Dhakal B, Dias A, Efebera Y, Faisal MS, Gowda L, Hashmi H, Mirza AS, Mohan M, Narra R, Rosko AE, Schroeder M, Nishihori T, Landau H, Usmani S, Pasquini MC, Akhtar OS, Sidana S, Patel KK. Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study. Blood Cancer J. 2026 Apr 14; 16(1).
-
Hashmi H, Sebastian T, Rajeeve S, Farzana T, Firestone RS, Jurgens EM, Miller KC, Maura F, Lesokhin AM, Tan CR, Shah GL, Korde N, Landau HJ, Merz M, Scordo M, Hassoun H, Maclachlan KH, Shah UA, Hultcrantz ML, Derkach A, Nemirovsky D, Giralt S, Mailankody S, Usmani SZ. Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma. Blood Cancer J. 2026 Apr 12; 16(1).
-
Koumpouras F, Caricchio R. Cellular therapies for rheumatic disease. Curr Opin Rheumatol. 2026 May 01; 38(3):155-162.
-
Hansen DK, Lu X, Castaneda Puglianini O, Zhang E, Usmani SZ, Sachdev R, Perciavalle M, De Wiest D, Huo S, Lee S, Qureshi ZP, Jagannath S. Comparative cost per responder analysis of ciltacabtagene autoleucel and real-world standard of care therapy in patients with lenalidomide-refractory multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2026 Mar; 26(3):369-378.
-
Itoh-Nakadai A, Liang M, Shindo M, Bibi C, Tomizawa-Murasawa M, Fujiki S, Kaneko A, Kanamaru E, Hashimoto M, Kajita H, Ando Y, Kojima M, Moody J, Iwasaki M, Takagi S, Nakagawa R, Agrawal S, Amitani-Iijima H, Sato K, Sorimachi Y, Suzuki N, Fukami T, Hanada K, Morita S, Katsura K, Matsumoto T, Kobayashi M, Kato M, Negishi Y, Shirouzu M, Najima Y, Takubo K, Hon CC, Uchida N, Taniguchi S, Momozawa Y, Carninci P, Shultz LD, Saito Y, de Hoon M, Shin JW, Ishikawa F. CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting. Nat Commun. 2026 Jan 26; 17(1):101.
-
Maheswaran S, Gordon CD, Chen EC, Patel SA. Challenges and Solutions to Implementation of Chimeric Antigen Receptor Therapies in Acute Myeloid Leukemia. Eur J Haematol. 2026 May; 116(5):501-511.
-
Gerber JM, Dehdashtian E, Hu G, Gregoire C, Borie D, Bindal P, Cerny J, Geara A, Schett G, Caricchio R. Successful autologous CD19 CAR T cell therapy following severe lupus flare during immunosuppressive washout in refractory lupus nephritis. Lupus Sci Med. 2025 Nov 19; 12(2).
-
Rejeski K, Sanz J, Fei T, Nair MS, Hashmi H, Avigdor A, Beyar-Katz O, B?cklein VL, Curran KJ, Einarsdottir S, Esensten JH, Glaubach N, Golan-Accav N, Gomez-Llobell M, Halamis I, Itzhaki O, Locke FL, Mailankody S, Marcus R, Maus MV, Palomba ML, Park JH, Pasquini M, Raj S, Rajeeve S, Salles G, Scordo M, Shah GL, Shimoni A, Subklewe M, Tix T, Usmani SZ, Valid O, Valtis YK, Zuckerman T, Shah NN, Perales MA, Shouval R. T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy. Blood. 2025 Aug 14; 146(7):834-846.
-
Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, Delgado J, Grover N, Haverkos B, de Lima M, Malone A, Mussetti A, Nieto Y, Pawarode A, Pearson L, Solh M, Sureda A, Tun AM, Wudhikarn K, Yamshon S, Shadman M, Turtle CJ, Hamadani M, Herrera AF. CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis. Am J Hematol. 2025 10; 100(10):1792-1802.